Recon: Pfizer, Novo escalate bidding war over Metsera; Merck lands $700M from Blackstone to develop investigational cancer drug
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- Experts worry FDA’s credibility is being shredded by scandal and ‘soap opera’ (STAT)
- Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates (STAT)
- Breaking: Lilly and Novo near White House deal on obesity drug prices (Endpoints)
- That $40 Billion Tylenol Deal Is Both Cheap and Risky (Bloomberg)
- Amgen profit beats estimates, weight-loss data due by year-end (Reuters)
- Prescription Pulse: More Tidmarsh Fallout (Politico)
- New FDA turmoil throws agency's reliability into question (Axios)
- Swiss biotech returns to Boehringer Ingelheim to partner on autoimmune T cell engager (Endpoints)
- US, Canada Face Unwelcome Measles Milestone Due to Outbreaks (Endpoints)
- Mandatory bird housing imposed in England as bird flu spreads (Reuters)
- EU Biotech Act: Careful Drafting Needed To Protect SMEs From ‘Over-Regulation’ (Pink Sheet)
- Sarepta Therapeutics’ dismal quarter marred by drug failures and a long list of excuses (STAT)
- A miracle pill for Parkinson’s is 50 years old. Why can’t most of the world get it? (STAT)
- As pharma pour billions in US manufacturing, CDMOs see future opportunities (Endpoints)
- Alvotech plant issues foil another FDA review, this time for Teva-partnered Simponi biosimilar (Fierce Pharma)
- The Tests They Are A-Changing: FDA Takes Action on Biosimilars (FDA Law Blog)
- Compass Pathways expects earlier FDA approval decision on its psilocybin drug (STAT)
- Microdosing aims to extend the lifespan of the GLP-1 compounding market (STAT)
- Jennifer Doudna spinoff aims to turn patients’ immune cells into CAR-T fighters with single shot (STAT)
- Incyte, Prelude ink rare blood cancer pact; Merck takes back rights to Prometheus asset (Endpoints)
- Pfizer cuts 11 R&D programs, reports revenue decline (Endpoints)
- Blackstone to pay Merck $700M to fund development of antibody-drug conjugate (Endpoints)
- Vertex’s Cystic Fibrosis Sales Beat, as Newer Drugs Miss (Bloomberg)
- Epilepsy Cell Therapy NRTX-1001 Among Trio Of Drugs To Win EMA PRIME Designations (Pink Sheet)
- Arcutis adds '90210' star power to skin condition awareness push (Fierce Pharma)
- Insulet campaign takes aim at workplace challenges for people with diabetes (Fierce Pharma)
- Philips New Orders Rise on Robust Demand in North America (Bloomberg)
- Dexcom recalls G6 CGM app over software problem (MedTech Dive)
- Neuromodulation Tech Raises Billions Despite Commercial Uncertainty (MedTech Insight)
- Surgery-Imaging Firm Ultragreen.ai Starts Gauging Interest for Singapore IPO (Bloomberg)
- Trump administration says SNAP will be partially funded in November (STAT)
- Brashears gets confirmation hearing for USDA Undersecretary for Food Safety appointment (Food Safety News)
- UnitedHealth pays its own physician groups 17% more than outside ones, study shows (STAT)
- GoodRx wants in on TrumpRx as it grows its work with pharmaceutical manufacturers (Endpoints)
- Florida’s vaccine mandate rollback stirs fear for immunocompromised (The Hill)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
